

## 文 献

1. Muller F. Korreferet. Morbus Brightii, Verhandl. Deut Path GesellMerano 1905 : 9 : 64-99.
2. Volhard F, Fahr T. Die Brightsche Nierenkrankheit. Berlin, 1914 : 33-35.
3. Sharpstone P, Ogg CS, Cameron JS. Nephrotic syndrome due to primary renal disease in adults : II . A controlled trial of prednisolone and azathioprine. Br Med J 1969 ; 2 (5656) : 535-539.
4. 上田 泰. 総括研究報告. 厚生省特定疾患ネフローゼ症候群調査研究班昭和 48 年度研究業績. 1974 : 7-9.
5. 東條静夫. 治療・予後分科会まとめ. 厚生省特定疾患ネフローゼ症候群調査研究班昭和 49 年度研究業績, 1975 : 88-89.
6. 堺 秀人. 進行性腎障害調査研究班 平成 10 年度研究業績. 1999 : 55-65.
7. 堺 秀人, 黒川 清, 斉藤喬雄, 椎木英夫, 西 慎一, 御手洗哲也, 横山 仁, 吉村吾志夫, 頼岡徳在. 難治性ネフローゼ症候群 (成人例) の診療指針. 日腎会誌 2002 ; 44 : 751-761.
8. Shiiki H, Saito T, Nishitani Y, Mitarai T, Yorioka N, Yoshimura A, Yokoyama H, Nishi S, Tomino Y, Kurokawa K, Sakai H. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004 ; 65 : 1400-1407.
9. Report of the International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1981 ; 98 : 561-564.
10. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. Kidney Int 2007 ; 72 : 1429-1447.
11. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007 ; 18 : 1899-1904.
12. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999 ; 56 : 2220-2226.
13. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy. definition and relevance of a partial remission. Kidney Int 2004 ; 66 : 1199-1205.
14. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotrophic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006 ; 47 : 233-240.
15. Ballarin J, Poveda R, Ara J, Pérez L, Calero F, Grinyó JM, Romero R. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil : results of a pilot study. Nephrol Dial Transplant 2007 ; 22 : 3196-3201.
16. Ruggenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein : creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998 ; 316 (7130) : 504-509.
17. Beatty OL, Ritchie CM, Bell PM, Hadden DR, Kennedy L, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes : an eight-year follow-up study. Diabet Med 1995 ; 12 : 261-266.
18. 渡辺 毅. 難治性ネフローゼ症候群の治療に関する研究. 進行性腎障害に関する調査研究 平成 21 年度総括・分担研究報告書 (松尾清一主任研究者). 2010 : 35-43.
19. 横山 仁, 田口 尚. 腎臓病総合レジストリーの構築とその解析に関する研究, 進行性腎障害に関する調査研究 平成 21 年度総括・分担研究報告書 (松尾清一主任研究者). 2010 : 23-34.
20. Palmer BF, Alpern RJ. Pathogenesis of edema formation in the nephrotic syndrome. Kidney Int 1997 ; 59

(Suppl) : S21-S27.

21. Koomans HA, Kortlandt W, Geers AB, Dorhout Mees EJ. Lowered protein content of tissue fluid in patients with the nephrotic syndrome : observations during disease and recovery. *Nephron* 1985 ; 40 : 391-395.
22. Dorhout Mees EJ, Geers AB, Koomans HA. Blood volume and sodium retention in the nephrotic syndrome : a controversial pathophysiological concept. *Nephron* 1984 ; 36 : 201-211.
23. Vande Walle JG, Donckerwolcke RA, van Isselt JW, Derkx FH, et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. *Lancet* 1995 ; 346 : 148-152.
24. Orth SR, Ritz E. The nephrotic syndrome. *N Engl J Med* 1998 ; 338 : 1202-1211.
25. 日本高血圧学会高血圧治療ガイドライン作成委員会. 高血圧治療ガイドライン 2009. 2009.
26. 日本腎臓学会. エビデンスに基づく CKD 診療ガイドライン 2009. 東京 : 東京医学社, 2009.
27. 日本腎臓学会. CKD 診療ガイド 2009, 東京 : 東京医学社, 2009.
28. Brater DC. Diuretic therapy. *N Engl J Med* 1998 ; 339 : 387-395.
29. Wilcox CS. New insights into diuretic use in patients with chronic renal disease. *J Am Soc Nephrol* 2002 ; 13 : 798-805.
30. Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. *Kidney Int* 1995 ; 55 : 629-634.
31. Akcicek F, Yalniz T, Basci A, Ok E, Mees EJ. Diuretic effect of frusemide in patients with nephrotic syndrome : is it potentiated by intravenous albumin? *BMJ* 1995 ; 310 : 162-163.
32. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. *Kidney Int* 1987 ; 32 : 198-203.
33. Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. *J Am Soc Nephrol* 2000 ; 11 : 1100-1105.
34. Ostermann M, Alvarez G, Sharpe MD, Martin CM. Frusemide administration in critically ill patients by continuous compared to bolus therapy. *Nephron Clin Pract* 2007 ; 107 : c70-76.
35. Rybak LP. Furosemide ototoxicity : clinical and experimental aspects. *Laryngoscope* 1985 ; 95 : 1-14.
36. Perico N, Remuzzi G. Edema of the nephrotic syndrome : the role of the atrial peptide system. *Am J Kidney Dis* 1993 ; 22 : 355-366.
37. Koomans HA, Geers AB, vd Meiracker AH, Roos JC, Boer P, Dorhout Mees EJ. Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome. *Am J Nephrol* 1984 ; 4 : 227-234.
38. Yoshimura A, Inui K, Nemoto T, Uda S, Sugeno Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T. Aggravation of minimal change nephrotic syndrome by administration of human albumin. *Clin Nephrol* 1992 ; 37 : 109-114.
39. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* 1993 ; 329 : 1456-1462.
40. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001 ; 345 : 851-860.
41. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* 1997 ; 349 : 1857-1863.
42. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. *J Am Soc Nephrol* 2007 ; 18 : 1959-1965.
43. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease : a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009 ; 4 : 542-551.
44. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2

- diabetes and nephropathy. *N Engl J Med* 2008 ; 358 : 2433-2446.
45. Grekas D, Alivannis P, Kalekou H, Syrganis C, Tourkantonis A. Are antiplatelet agents of value in the treatment of chronic glomerular disease? *Nephrol Dial Transplant* 1987 ; 2 : 377-379.
  46. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. *Clin Exp Nephrol* 2006 ; 10 : 268-273.
  47. Wheeler DC. Lipid abnormalities in the nephrotic syndrome : the therapeutic role of statins. *J Nephrol* 2001 ; 14 (Suppl 4) : S70-75.
  48. van Dokkum RP, Henning RH, de Zeeuw D. Statins cholesterol, blood pressure and beyond. *J Hypertens* 2002 ; 20 : 2351-2353.
  49. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes : a meta-analysis. *J Am Soc Nephrol* 2006 ; 17 : 2006-2016.
  - 49a. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R : SHARP Investigators. : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. *LANCET* 2011 ; 377 : 2181-2192.
  50. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. *Pharmacol Res* 2010 ; 61 : 58-61.
  51. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y : K-FLAT study group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. *Nephron* 2001 ; 89 : 408-415.
  52. Muso E, Nishizawa Y, Saito T, Mune M, Hirano T, Hattori M, Yorioka N, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). *Clin Nephrol* 2007 ; 67 : 341-344.
  53. Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. *Kidney Int* 1986 ; 29 : 572-577.
  54. Maroni BJ, Staffeld C, Young VR, Manatunga A, Tom K. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. *J Clin Invest* 1997 ; 99 : 2479-2487.
  55. The Merck Manuals <http://www.merck.com/mmpe/index.html>.
  56. 日本腎臓学会. 腎疾患患者の生活指導・食事療法ガイドライン. *日腎会誌* 1997 ; 39 : 1-37.
  57. Poortmans JR, Vanderstraeten J. Kidney function during exercise in healthy and diseased humans. An update. *Sports Med* 1994 ; 18 : 419-437.
  58. Miura H, Fukui H, Hayano K, Otsuka Y, Hattori S. A case of minimal change nephrotic syndrome associated with acute renal failure after excessive exercise. *Nippon Jinzo Gakkai Shi* 1993 ; 35 : 387-391.
  59. 佐藤文三. ステロイドの薬理学. 佐藤文三 (編) ステロイド薬の選び方と使い方. 東京 : 南江堂, 1999 : 9-24.
  60. Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, Nakajima N, Nishibori Y, Shibata T, Kohsaka T, Higashihara E, Tanaka H, Watanabe H, Nagasawa T, Awa S. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. *Kidney Int* 1999 ; 56 : 65-73.
  61. 小林 豊. ステロイド薬. 横野博史 (編) プラクティカル内科シリーズ 10 腎炎・ネフローゼ. 東京 : 南江堂, 2000 : 53-60.
  62. Imbasciati E, Gusmano R, Edefonti A, Zucchelli P, Pozzi C, Grassi C, Della Volpe M, Perfumo F, Petrone P, Picca M, et al. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal

- change nephrotic syndrome. *Br Med J (Clin Res Ed)* 1985 ; 291 : 1305-1308.
63. Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. *Cochrane Database Syst Rev* (1) : CD001537, 2008.
  64. 東條静雄, 本田西男, 成田光陽, 酒井 紀, 伊藤隆太. スレブタン酸メチルプレドニゾロン (U-67, 590A) の成人原発ネフローゼ症候群に対する臨床評価 (第三相 2 重盲検試験). *腎と透析* 1994 ; 36 : 1053-1064.
  65. 東條静雄, 本田西男, 成田光陽, 酒井 紀, 伊藤隆太. スレブタン酸メチルプレドニゾロン (U-67, 590A) の成人原発ネフローゼ症候群に対する臨床評価 (後期第二相 2 重盲検試験). *腎と透析* 1994 ; 36 : 647-660.
  66. 川合真一. ステロイドの種類, 代謝動態, 相互作用. 川合真一 (編) ステロイドの上手な使い方, 東京 : 永井書店, 2004 : 16-22.
  67. 近藤大介, 上野光博, 西 慎一, 成田一衛, 下条文武. ステロイド薬の適応と使い方. *内科* 2004 ; 94 : 41-45.
  68. 折茂 肇. ステロイド性骨粗鬆症. 骨粗鬆症の予防と治療ガイドライン 2006 年版. 2006 : 106-107.
  69. 坪内博仁, 熊田博光, 清澤研道, 持田 智, 坂井田 功, 田中栄司, 市田隆文, 溝上雅史, 鈴木一幸, 與芝眞彰, 森脇久隆, 日比紀文, 林 紀夫, 國土典宏, 藤澤知雄, 石橋大海, 菅原寧彦, 八橋 弘, 井戸章雄, 滝川康裕, 井上和明, 桶谷 真, 宇都浩文, 中山伸朗, 内木隆文, 多田慎一郎, 木曾真一, 矢野公士, 遠藤龍人, 田中靖人, 梅村武司, 熊谷幸太郎. 免疫抑制・化学療法により発症する B 型肝炎対策 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 劇症肝炎分科会および「肝硬変を含めたウイルス肝炎疾患の治療の標準化に関する研究」班合同報告. *肝臓* 2009 ; 50 : 38-42.
  70. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. *Nat Med* 2008 ; 14 : 931-938.
  71. Mathieson PW. Proteinuria and immunity--an overstated relationship? *N Engl J Med* 2008 ; 359 : 2492-2494.
  72. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvardi E, Gusmano R, Locatelli F, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. *Kidney Int* 1993 ; 43 : 1377-1384.
  73. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. *Cochrane Database Syst Rev* 2008 Jul 16 ; (3) : CD003233.
  74. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. Cyclosporine in patients with steroid-resistant membranous nephropathy : a randomized trial. *Kidney Int* 2001 ; 59 : 1484-1490.
  75. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. *Nephrol Dial Transplant* 2006 ; 21 : 3127-3132.
  76. 高久史磨, 杉町圭蔵, 北村惣一郎, 内山 充, 乾 賢一 (監) : シクロスポリン, 日本医薬品集 医療薬 2011 年版. 東京 : じほう, 2010 : 1095-1102.
  77. Shirai S, Yasuda T, Tsuchida H, Kuboshima S, Konno Y, Shima Y, Sato T, Hatta S, Masuhara K, Kimura K. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. *Clin Exp Nephrol* 2009 ; 13 : 123-129.
  78. Kusaba T, Konno Y, Hatta S, Fujino T, Yasuda T, Miura H, Sasaki H, Okabayashi J, Murao M, Sakurada T, Imai G, Shirai S, Kuboshima S, Shima Y, Ogimoto G, Sato T, Masuhara K, Kimura K. More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome. *Pharmacotherapy* 2005 ; 25 : 52-58.
  79. Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, Morozumi K. Benefits of cyclosporine absorption profiling in nephrotic syndrome : preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. *Nephrology* 2007 ; 12 : 197-204.
  80. 斉藤喬雄, 岩野正之, 佐藤 博, 西 慎一, 松本紘一, 御手洗哲也, 横山 仁, 吉村吾志夫, 頼岡徳在, 片岡泰文, 武曾恵理, 笹富佳江, 小河原 悟, 首藤英樹, 渡辺真穂, 上野雅代. 難治性ネフローゼ症候群の治療に関する研究. 進行性腎障害に関する調査研究 平成 21 年度総括・分担研究報告書 (松尾清一主

- 任研究者). 2010 : 99-109.
81. 武田朝美, 両角國男. カルシニューリンインヒビター. 腎と透析 2005 ; 59 増刊号 : 242-246.
  82. 打田和治. シクロスポリン血中濃度測定精度管理結果報告. 今日の移植 2009 ; 22 : 632-638.
  83. Tang S, Tang AW, Tam MK, Ho YW. Use of tacrolimus in steroid-and cyclophosphamide-resistant minimal change nephrotic syndrome. *Am J Kidney Dis* 2003 ; 42 : E13-15.
  84. 萩原大二郎, 塩田浩平. プログラフの妊娠時使用経験. 今日の移植 2004 ; 17 : 451-455.
  85. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C ; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003 ; 349 : 36-44.
  86. Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis. *Clin Nephrol* 2008 ; 69 : 433-435.
  87. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, Shiiki H, Makino H, Sato H, Ishikawa I, Maeda K, Tomita K, Arakawa M, Ishida M, Sato M, Nagase M, Kashiwara N, Yorioka N, Koike T, Saito T, Harada T, Mitarai T, Sugisaki T, Nagasawa T, Tomino Y, Nojima Y, Kobayashi Y, Sakai O. A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). *Clin Exp Nephrol* 2004 ; 8 : 117-126.
  88. 斉藤喬雄, 岩野正之, 佐藤 博, 西 慎一, 松本紘一, 御手洗哲也, 横山 仁, 吉村吾志夫, 頼岡徳在, 片岡泰文, 武曾恵理, 笹富佳江, 小河原 悟, 首藤英樹, 安部泰弘, 伊藤建二, 渡辺真穂, 上野雅代. 難治性ネフローゼ症候群の治療に関する研究. 平成 22 年度厚生労働科学研究費補助金 (難治性疾患克服研究事業) 難治性ネフローゼ症候群分科会分担研究報告書. 2011.
  89. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothnathan R, Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. *Kidney Int* 2002 ; 61 : 1098-1114.
  90. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. *Nat Clin Pract Nephrol* 2009 ; 5 : 132-142.
  91. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. *Am J Kidney Dis* 1995 ; 25 : 862-875.
  92. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. *Ann Intern Med* 2001 ; 135 : 248-257.
  93. Imai H, Kodama T, Yasuda T, Nakamoto Y, Miura AB. Inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide : an index of cyclophosphamide therapy. *Nephrol Dial Transplant* 1994 ; 9 : 1240-1249.
  94. Cox R, Goorha S, Irving CC. Inhibition of DNA methylase activity by acrolein. *Carcinogenesis* 1988 ; 9 : 463-465.
  95. Bryant BM, Jarman M, Ford HT, Smith IE. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. *Lancet* 1980 ; 2 (8196) : 657-659.
  96. Vose JM, Reed EC, Pippert GC, Anderson JR, Bierman PJ, Kessinger A, Spinolo J, Armitage JO. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation : a randomized trial. *J Clin Oncol* 1993 ; 11 : 1306-1310.
  97. 血管炎症候群の診療ガイドライン (Guideline for Management of Vasculitis Syndrome, JCS 2008). *Circulation Journal* 2008 ; 72 (Suppl IV) : 1254-1310.
  98. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. *Clin J Am Soc Nephrol* 2008 ; 3 : 1652-1659.



99. Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome. *Clin Nephrol* 2009 ; 72 : 69-72.
100. Hofstra JM, Deegens JK, Wetzels JF. Rituximab : effective treatment for severe steroid-dependent minimal change nephrotic syndrome? *Nephrol Dial Transplant* 2007 ; 22 : 2100-2102.
101. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004 ; 351 : 1296-1305.
102. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. *Kidney Int* 1993 ; 44 : 638-642.
103. Fried LF, Orchard TJ, Kasiske BL : for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease : a metanalysis. *Kidney Int* 2001 ; 59 : 260-269.
104. Tonelli M, Moyé L, Sacks F, Cole T, Curham G. Effect of pravastatin on loss of renal function in patients with moderate chronic renal insufficiency and cardiovascular disease. *J Am Soc Nephrol* 2003 ; 14 : 1605-1613.
105. Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. *Clin Nephrol* 2004 ; 62 : 245-259.
106. Yashiro M, Muso E, Shio H, Sasayama S. Amelioration of hypercholesterolaemia by HMG-CoA reductase inhibitor (Pravastatin) improved platelet hyperaggregability in nephrotic patients. *Nephrol Dial Transplant* 1994 ; 9 : 1842-1843.
107. Rayner BL, Byrne MJ, van Zyl Smit R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. *Clin Nephrol* 1996 ; 46 : 219-224.
108. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. *Kidney Int* 2002 ; 62 : 550-555.
109. Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, Wada T, Naito T, Ikeda K, Goshima S, Takasawa K, Kobayashi K. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. *Am J Kidney Dis* 1994 ; 24 : 427-436.
110. Taube D, Chapman S, Brown Z, Williams DG. Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome. *Clin Nephrol* 1981 ; 15 : 286-290.
111. Centers for Disease Control and Prevention. Preventing pneumococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 1997 ; 46 (RR-8) : 1-24.
112. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2000 ; 49 (RR-9) : 1-35.
113. Cisneros JM, Muñoz P, Torre-Cisneros J, Gurgui M, Rodriguez-Hernandez MJ, Aguado JM, Echaniz A. Pneumonia after heart transplantation : a multi-institutional study. Spanish Transplantation Infection Study Group. *Clin Infect Dis* 1998 ; 27 : 324-331.
114. Wazir JF, Ansari NA. *Pneumocystis carinii* infection. Update and review. *Arch Pathol Lab Med* 2004 ; 128 : 1023-1027.
115. Gerrard JG. *Pneumocystis carinii* pneumonia in HIV-negative immunocompromised adults. *Med J Aust* 1995 ; 162 : 233-235.
116. Yale SH, Limper AH. *Pneumocystis carinii* pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. *Mayo Clin Proc* 1996 ; 71 : 5-13.
117. Thomas CF, Limper AH. *Pneumocystis* pneumonia. *N Engl J Med* 2004 ; 350 : 2487-2498.
118. Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K, Adachi T, Tanaka Y. Detection of *Pneumocystis carinii* by DNA amplification in patients with connective tissue diseases : re-evaluation of clinical features of *P. carinii* pneumonia in rheumatic diseases. *Rheumatology* 2004 ; 43 : 479-485.

119. Rodriguez M, Fishman JA. Prevention of infection due to *Pneumocystis spp.* in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-782.
120. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-1107.
121. 日本結核病学会 (編). 結核診療ガイドライン. VI. 潜在性結核感染症, 東京: 南江堂, 2006 : 89-107.
122. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985 ; 28 : 429-439.
123. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis : acute and chronic. Am J Med 1980 ; 69 : 819-827.
124. Cherng SC, Huang WS, Wang YF, Yang SP, Lin YF. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 2000 ; 25 : 167-172.
125. Glasscock RJ. Prophylactic anticoagulation in nephrotic syndrome : a clinical conundrum. J Am Soc Nephrol 2007 ; 18 : 2221-2225.
126. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008 ; 121 : 226-230.
127. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome : results from a large retrospective cohort study. Circulation 2008 ; 117 : 224-230.
128. Wass VJ, Jarrett RJ, Chilvers C, Cameron JS. Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet 1979 ; 2 : 664-667.
129. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994 ; 45 : 578-585.
130. Bramham K, Hunt BJ, Goldsmith D. Thrombophilia of nephrotic syndrome in adults. Clin Adv Hematol Oncol 2009 ; 7 : 368-372.
131. 鶴田悠木, 新田孝作. ネフローゼ症候群: 診断と治療の進歩. I. 基礎と病態. 2. 合併症と対策. 日内会誌 2009 ; 98 : 993-997.
132. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン第2版, 2009.
133. Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 1986 ; 25 : 75-80.
134. Al-Momen AK, Al-Abdul-Kareem H. Potentiation of the action of warfarin by bezafibrate in patients with the nephrotic syndrome. Saudi J Kidney Dis Transplant 1994 ; 5 : 12-16.
135. Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron 1995 ; 69 : 20-28.
136. Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med 1966 ; 64 : 41-51.
137. Row PG, Cameron JS, Turner DR, Evans DJ, White RH, Ogg CS, Chantler C, Brown CB. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 1975 ; 44 : 207-239.
138. Cahen R, Francois B, Trolliet P, Gilly J, Parchoux B. Aetiology of membranous glomerulonephritis : a prospective study of 82 adult patients. Nephrol Dial Transplant 1989 ; 4 : 757-758.
139. Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol 2003 ; 23 : 400-405.
140. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993 ; 22 : 5-10.
141. Zeng CH, Chen HM, Wang RS, Chen Y, Zhang SH, Liu L, Li LS, Liu ZH. Etiology and clinical characteristics of

- membranous nephropathy in Chinese patients. *Am J Kidney Dis* 2008 ; 52 : 691-698.
142. 矢野孝明, 若林久男, 赤本伸太郎, 谷内田真一, 岡野圭一, 臼杵尚志, 前田 肇. ネフローゼ症候群を合併した消化器悪性腫瘍に対して外科的治療を施行した 5 例の検討. *日消外会誌* 2006 ; 39 : 1627-1631.
  143. Kramer P, Sizoo W, Twiss EE. Nephrotic syndrome in Hodgkin's disease. Report of five cases and review of the literature. *Neth J Med* 1981 ; 24 : 114-119.
  144. Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma : report of 21 cases and review of the literature. *Kidney Int* 2006 ; 69 : 2251-2260.
  145. Knight A, Askling J, Granath F, Sparen P, Ekblom A. Urinary bladder cancer in Wegener's granulomatosis : risks and relation to cyclophosphamide. *Ann Rheum Dis* 2004 ; 63 : 1307-1311.
  146. Queille S, Luron L, Spatz A, Avril MF, Ribrag V, Duveillard P, Hiesse C, Sarasin A, Armand JP, Daya-Grosjean L. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. *Carcinogenesis* 2007 ; 28 : 724-731.
  147. Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. *J Clin Invest* 1970 ; 49 : 1103-1113.
  148. Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y. Distribution of IgG subclasses in membranous nephropathy. *Clin Exp Immunol* 1984 ; 58 : 57-62.
  149. Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. *Kidney Int* 1997 ; 51 : 270-276.
  150. Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. *Kidney Int* 2005 ; 68 : 302-310.
  151. Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, Kigawa A, Sawada K, Imai H. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. *Nephrol Dial Transplant* 2004 ; 19 : 574-579.
  152. Andreucci M, Federico S, Andreucci VE. Edema and acute renal failure. *Semin Nephrol* 2001 ; 21 : 251-256.
  153. Koomans HA. Pathophysiology of acute renal failure in idiopathic nephrotic syndrome. *Nephrol Dial Transplant* 2001 ; 16 : 221-224.
  154. Mandal AK, Baig M, Koutoubi Z. Management of acute renal failure in the elderly. Treatment options. *Drugs Aging* 1996 ; 9 : 226-250.
  155. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. *Kidney Int* 2002 ; 62 : 2223-2229.
  156. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. *BMJ* 2008 ; 336 : 1185-1189.
  157. Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. *Nephron* 1999 ; 82 : 205-213.
  158. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal change nephrotic syndrome in adults : response to corticosteroid therapy and frequency of relapse. *Am J Kidney Dis* 1991 ; 17 : 687-692.
  159. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. *Am J Kidney Dis* 2002 ; 39 : 503-512.
  160. Takei T, Koike M, Suzuki K, Shiota S, Itabashi M, Ohtsubo S, Sugiura H, Suzuki K, Kojima C, Takahashi M, Ino J, Ogawa T, Uchida K, Tsuchiya K, Yumura W, Nitta K. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. *Clin Exp Nephrol* 2007 ; 11 : 214-217.
  161. Nachman PH, Jennette JC, Falk RJ. Primary glomerular diseases. In : Brenner BM (ed) *Brenner & Rector's the kidney* 8th ed, Philadelphia : Saunders Elsevier, 2008 : 995-1000.
  162. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal-change disease : clinical characteristics, treatment, and outcomes. *Clin J Am Soc Nephrol* 2007 ; 2 : 445-453.
  163. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome : a long-term follow-up. *Kidney Int* 1986 ; 29 : 1215-1223.



164. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. *Br Med J* 1970 ; 3 : 421-426.
165. Coggins CH. Adult minimal change nephropathy : experience of the collaborative study of glomerular disease. *Trans Am Clin Climatol Assoc* 1986 ; 97 : 18-26.
166. Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN, Chan TM. Idiopathic minimal change nephrotic syndrome in older adults : steroid responsiveness and pattern of relapses. *Nephrol Dial Transplant* 2003 ; 18 : 1316-1320.
167. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. *Arbeitsgemeinschaft für Pädiatrische Nephrologie. Lancet* 1988 ; 1 (8582) : 380-383.
168. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. *Arbeitsgemeinschaft für Pädiatrische Nephrologie. Eur J Pediatr* 1993 ; 152 : 357-361.
169. Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. *Nephrol Dial Transplant* 1996 ; 11 : 2192-2201.
170. Matsumoto H, Nakao T, Okada T, Nagaoka Y, Takeguchi F, Tomaru R, Iwasawa H. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. *Intern Med* 2004 ; 43 : 668-673.
171. Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis : a multicenter study in Korea. *Clin Nephrol* 1995 ; 43 : 375-381.
172. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zarcchello G, Confalonieri R, Altieri P, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome : a multicentre randomized controlled trial. *Nephrol Dial Transplant* 1993 ; 8 : 1326-1332.
173. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A : minimal-change disease and focal-segmental glomerulosclerosis. *Collaborative Group of the French Society of Nephrology. Clin Nephrol* 1991 ; 35 (Suppl) : S37-S42.
174. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, Campbell K. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. *Arch Intern Med* 1986 ; 146 : 737-741.
175. 吉澤重人, 鈴木寿英, 上松瀬勝男. ステロイド抵抗性ネフローゼ症候群に対する LDL-アフェレシスの有効性に関する検討. *日腎会誌* 2003 ; 45 : 25-31.
176. Buemi M, Nostro L, Craschi E, Barilla A, Cosentini V, Aloisi C, Sofi T, Campo S, Frisina N. Statins in nephrotic syndrome : a new weapon against tissue injury. *Med Res Rev* 2005 ; 25 : 587-609.
177. Gheith OA, Sobh MA, Mohamed Kel-S, El-Baz MA, El-Husseini F, Gazarin SS, Ahmed HA, Rasem MW, Amer GM. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. *Nephron* 2002 ; 91 : 612-619.
178. Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome : non-specific strategies for treatment. *Nephrology (Carlton)* 2008 ; 13 : 45-50.
179. D'Agati VD, Fogo A, Bruijn J, Jennette JC. Pathological classification of focal segmental glomerulosclerosis : a working proposal. *Am J Kidney Dis* 2004 ; 43 : 368-382.
180. D'Agati VD. Podocyte injury in focal segmental glomerulosclerosis : Lessons from animal models. *Kidney Int* 2008 ; 73 : 399-406.
181. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. *Science* 2005 ; 308 (5729) : 1801-1804.
182. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden BW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental

- glomerulosclerosis. *Nat Genet* 2008 ; 40 : 1175-1184.
183. Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. *Kidney Int* 2010 ; 78 : 207-214.
  184. Marszal J, Saleem MA. The bioactivity of plasma factors in focal segmental glomerulosclerosis. *Nephron Exp Nephrol* 2006 ; 104 : e1-e5.
  - 184a. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J. : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. *Nat Med* 2011 ; 17 : 952-960.
  185. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. *Clin Nephrol* 1991 ; 36 : 53-59.
  186. Agarwal SK, Dash SC, Tiwari SC, Bhuyan UN. Idiopathic adult focal segmental glomerulosclerosis : a clinicopathological study and response to steroid. *Nephron* 1993 ; 63 : 168-171.
  187. Rydell JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults : presentation, course, and response to treatment. *Am J Kidney Dis* 1995 ; 25 : 534-542.
  188. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A, Passerini P, Farina M, Grassi C, Baroli A. Can prolonged treatment improve the prognosis of adults with FSGS? *Am J Kidney Dis* 1999 ; 34 : 618-625.
  189. Matalon A, Valeri A, Appel GB. Treatment of focal segmental glomerulosclerosis. *Semin Nephrol* 2000;20:309-317.
  190. Korbet SM. The treatment of primary focal segmental glomerulosclerosis. *Ren Fail* 2000 ; 22 : 685-696.
  191. Korbet SM. Treatment of primary focal and segmental glomerulosclerosis. *Kidney Int* 2002 ; 62 : 2301-2310.
  192. Hari P, Bagga A, Jidani N, Srivastava RN. Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. *Pediatr Nephrol* 2001 ; 16 : 901-905.
  193. Kirpekar R, Yorgin PD, Tune BM, Kim MK, Sibley RK. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. *Am J Kidney Dis* 2002 ; 39 : 1143-1152.
  194. Chang JW, Yang LY, Wang HH. Low-dose methylprednisolone pulse therapy in Chinese children with steroid resistant focal segmental glomerulosclerosis. *Pediatr Int* 2007 ; 49 : 349-354.
  195. Pena A, Bravo J, Melgosa M, Fernandez C, Meseguer C, Espinosa L, Alonso A, Picazo ML, Navarro M. Steroid-resistant nephrotic syndrome, long-term evolution after sequential therapy. *Pediatr Nephrol* 2007 ; 22 : 1875-1880.
  196. Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, Keller F, Kramer BK, Schollmeyer P, Risler T, Grabensee B : German Collaborative Glomerulonephritis Study Group. Cyclosporin A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. *Am J Kidney Dis* 2004 ; 43 : 10-18.
  197. Meyrier A. Treatment of focal segmental glomerulosclerosis with immunophilin modulation : when did we stop thinking about pathogenesis? *Kidney Int* 2009 ; 76 : 487-491.
  198. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. *Expert Opin Pharmacother* 2009 ; 10 : 615-628.
  199. Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M : Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2009 ; 24 : 2177-2185.
  200. 齊藤喬雄. 難治性ネフローゼ症候群の診断指針改定に向けて. *日腎会誌* 2008 ; 50 : 224.
  201. Tanaka H, Oki E, Tsuruga K, Sato N, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis : a clinicopathologic study by the Tohoku Pediatric Study Group. *Nephron Clin*

- Pract 2008 ; 110 : c73-79.
202. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis. *Jpn J Nephrol* 1988 ; 30 : 1153-1160.
  203. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. *Am J Kidney Dis* 2003 ; 42 : 1121-1130.
  204. Kida H, Asamoto T, Yokoyama H, Tomosugi N, Hattori N. Long-term prognosis of membranous nephropathy. *Clin Nephrol* 1986 ; 25 : 64-69.
  205. Glasscock RJ. Diagnosis and natural course of membranous nephropathy. *Sem Nephrol* 2003 ; 23 : 324-332.
  206. Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G. A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. *Kidney Int* 2000 ; 58 : 1732-1741.
  207. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med* 2009 ; 361 : 11-21.
  208. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G. Prognosis and untreated patients with idiopathic membranous nephropathy. *N Engl J Med* 1993 ; 329 : 85-89.
  209. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M ; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. *J Am Soc Nephrol* 2010 ; 21 : 697-704.
  210. 高久史麿, 杉町圭蔵, 北村惣一郎, 内山 充, 乾 賢一 (監). ミゾリビン, 日本医薬品集 医療薬 2011 年版. 東京 : じほう, 2010 : 2623-2625.
  211. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. *J Am Soc Nephrol* 1998 ; 9 : 444-450.
  212. 高久史麿, 杉町圭蔵, 北村惣一郎, 内山 充, 乾 賢一 (監). シクロホスファミド水和物, 日本医薬品集 医療薬 2010 年版. 東京 : じほう, 2009 : 1085-1089.
  213. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapy and future intervention for treatment of membranous nephropathy. *Sem Nephrol* 2003 ; 23 : 362-372.
  214. Rodicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity : long-term trial in renal transplantation patients. *J Cardiovasc Pharmacol* 2000 ; 35 (3 Suppl 1) : S7-11.
  215. West CD. Childhood membranoproliferative glomerulonephritis : an approach to management. *Kidney Int* 1986 ; 29 : 1077-1093.
  216. Cameron JS, Turner DR, Heaton J, Williams DG, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. *Am J Med* 1983 ; 74 : 175-192.
  217. Rennke HG. Secondary membranoproliferative glomerulonephritis. *Kidney Int* 1995 ; 47 : 643-656.
  218. Neary JJ, Conlon PJ, Croke D, Dorman A, Keogan M, Zhang FY, Vance JM, Pericak-Vance MA, Scott WK, Winn MP. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. *J Am Soc Nephrol* 2002 ; 13 : 2052-2057.
  219. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Würzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. *J Am Soc Nephrol* 2007 ; 18 : 2447-2456.

220. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* 1993 ; 328 : 465-470.
221. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. *Am J Med* 1999 ; 106 : 347-354.
222. Martinelli R, Noblat AC, Brito E, Rocha H. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis : influence of therapy. *Kidney Int* 1989 ; 35 : 1227-1233.
223. Yamabe H, Johnson RJ, Gretch DR, Osawa H, Inuma H, Sasaki T, Kaizuka M, Tamura N, Tsunoda S, Fujita Y. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. *J Am Soc Nephrol* 1995 ; 6 : 220-223.
224. Nasr SH, Markowitz GS, Stokes MB, Seshan SV, Valderrama E, Appel GB, Aucouturier P, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits : a distinct entity mimicking immune-complex glomerulonephritis. *Kidney Int* 2004 ; 65 : 85-96.
225. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, Nadasdy T, D'Agati VD. Proliferative glomerulonephritis with monoclonal IgG deposits. *J Am Soc Nephrol* 2009 ; 20 : 2055-2064.
226. Masai R, Wakui H, Togashi M, Maki N, Ohtani H, Komatsuda A, Sawada K. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. *Clin Nephrol* 2009 ; 71 : 9-20.
227. Ahmed M, Solangi K, Abbi R, Adler S. Nephrotic syndrome, renal failure, and renal malignancy : an unusual tumor-associated glomerulonephritis. *J Am Soc Nephrol* 1997 ; 8 : 848-852.
228. Suzuki J, Suzuki S, Nozawa R, Kawasaki Y, Suzuki H. Membranoproliferative glomerulonephritis associated with hereditary deficiency of the 4th component of complement. *Clin Nephrol* 2003 ; 60 : 279-283.
229. Kamar N, Rostaing L, Alric L. Treatment of hepatic C-virus-related glomerulonephritis. *Kidney Int* 2006 ; 69 : 436-439.
230. Donadio JV Jr, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. *Am J Kidney Dis* 1989 ; 14 : 445-451.
231. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. *Kidney Int* 2006 ; 69 : 504-511.
232. Tarshish P, Bernstein J, Tobin JN, Edelmann CM, Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. *Pediatr Nephrol* 1992 ; 6 : 123-130.
233. Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I : limited steroid therapy. *Kidney Int* 1992 ; 41 : 1606-1612.
234. Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis : a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). *Nephrol Dial Transplant* 1994 ; 9 : 619-622.
235. Jones G, Juszczak M, Kingdon E, Harber M, Sweny P, Burns A. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. *Nephrol Dial Transplant* 2004 ; 19 : 3160-3164.
236. Arneil GC. 164 children with nephrosis. *Lancet* 1961 ; 18 : 1103-1110.
237. 日本腎臓学会 (編). CKD 診療ガイドライン 2009. 20. 高齢者の CKD 診療 : 6. 高齢者と腎移植. 東京 : 東京医学社, 2009 : 247-248.
238. Cattran D. Management of membranous nephropathy : when and what for treatment. *J Am Soc Nephrol* 2005 ; 16 : 1188-1194.